上海和香港2021年6月(yue)2日(ri) /美通社/ -- 致力于(yu)(yu)研(yan)發和商(shang)業(ye)化創新腫瘤療法的(de)領先生物制(zhi)藥(yao)公司--德琪醫藥(yao)有限公司（簡稱“德琪醫藥(yao)”，香港聯(lian)交(jiao)所(suo)股票(piao)代(dai)碼：6996.HK）今日(ri)宣布，同類首款選擇性核輸出抑(yi)制(zhi)劑——塞(sai)利(li)尼索（selinexor）12項研(yan)究及成果(guo)入選歐洲血液學協(xie)會（EHA）年會。此屆 EHA 會議將(jiang)于(yu)(yu)6月(yue)9日(ri)至6月(yue)17日(ri)在線上召開(kai)。

線上摘要

Phase 2 MARCH study of oral ATG-010 plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously exposed to an immunomodulatory agent and a proteasome inhibitor.

摘(zhai)要編(bian)號：PB1670

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

摘要編號：S188

Selinexor containing regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies.

摘要編(bian)號：EP1002

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed/refractory multiple myeloma (MM).

摘要編號：EP1008

Ciltacabtagene Autoleucel versus selinexor + dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) treated with ≥ 3 lines of prior therapy：A matching adjusted indirect comparison.

摘要編號：EP1049

Cost effectiveness comparison of belantamab mafodotin and selinexor in relapsed refractory multiple myeloma.

摘要(yao)編(bian)號：EP1173

Lymphocyte count effect on efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma（DLBCL）：A post-hoc analysis from phase 2B SADAL study.

摘要編號(hao)：EP530

Genomic correlates of respones to selinexor in multiple myeloma from the BOSTON study reveal a predictive signature.

摘要編號：EP936

Effects of selinexor on previously treated multiple myeloma (MM) with RAS-mutations.

摘要編號：EP966

Efficacy and safety of selinexor, bortezomib, and dexamethasone based on refractory status to lenalidomide in patients with previously treated multiple myeloma：A post-hoc analysis of the BOSTON study.

摘要編號(hao)：EP974

Survival among older patients with previously treated multiple myeloma treated with selinexor，bortezomib, and dexamethasone (XVd) in the BOSTON study.

摘要編號：EP976

Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.

摘(zhai)要(yao)編(bian)號：EP924

關于德琪醫藥

德(de)(de)琪(qi)醫(yi)(yi)藥(yao)有限公司（簡稱“德(de)(de)琪(qi)醫(yi)(yi)藥(yao)”，香港聯交(jiao)所股票代碼：6996.HK）是一家以(yi)研(yan)發為(wei)(wei)驅動的(de)生(sheng)物(wu)制藥(yao)領先企業(ye)，致力于(yu)為(wei)(wei)亞(ya)太乃至全球患者(zhe)提供最領先的(de)療法(fa)(fa)，治療腫瘤及其他危及生(sheng)命的(de)疾病。自2017年正式(shi)運營(ying)以(yi)來(lai)，德(de)(de)琪(qi)醫(yi)(yi)藥(yao)通過合作引進和自主(zhu)研(yan)發，建立(li)了(le)一條從(cong)臨(lin)(lin)床(chuang)(chuang)前(qian)到臨(lin)(lin)床(chuang)(chuang)階段不斷延展的(de)豐富產(chan)品管線。目前(qian)，德(de)(de)琪(qi)醫(yi)(yi)藥(yao)已(yi)在多(duo)個亞(ya)太市(shi)場獲得15個臨(lin)(lin)床(chuang)(chuang)批(pi)件（IND），并遞(di)交(jiao)了(le)5個新藥(yao)上市(shi)申請（NDA）。德(de)(de)琪(qi)醫(yi)(yi)藥(yao)將(jiang)以(yi)“醫(yi)(yi)者(zhe)無(wu)疆，創新永(yong)續”為(wei)(wei)愿景，專注于(yu)同類(lei)(lei)首款和同類(lei)(lei)最優(you)療法(fa)(fa)的(de)早(zao)期(qi)研(yan)發、臨(lin)(lin)床(chuang)(chuang)研(yan)究、藥(yao)物(wu)生(sheng)產(chan)及商(shang)業(ye)化(hua)，解決亟(ji)待(dai)滿足的(de)臨(lin)(lin)床(chuang)(chuang)需(xu)求。